Security key
690469101
- Security type / class
- Equity / COMMON STOCK
- Total 13F shares
- 46,022,725
- Total 13F value
- $35,395,023
- Share change
- -4,122,326
- Put/Call ratio
- 1.9%
- SEC-reported price per share
- $0.77
- Number of holders
- 72
- Value change
- -$20,868,716
- Number of buys
- 34
- Number of sells
- 44
- Shares outstanding
- 186,437,735
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2024
Institutions
72
Top holders
10
OVID full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q3 2024
Previous quarter: Q1 2024
Ovid Therapeutics Inc. SEC filings
Ovid Therapeutics Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 690469101
Recent filing periods:
Ownership snapshot
Top reported holders of OVID - Ovid Therapeutics Inc. - COMMON STOCK (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
TAKEDA PHARMACEUTICAL CO LTD
Disclosed value leader
TAKEDA PHARMACEUTICAL CO LTD
Comparable rows
15/15
Latest evidence
31 Mar 2024
13F
Lead comparable stake: 4%
Showing 1-6 of 15 holder rows.
Quick read
TAKEDA PHARMACEUTICAL CO LTD leads the comparable SEC ownership view at 4%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens TAKEDA PHARMACEUTICAL CO LTD's linked filing trail.
Comparable ownership
Top 5
TAKEDA PHARMACEUTICAL CO LTD
4%
EcoR1 Capital, LLC
3.3%
Rubric Capital Management LP
2.9%
BlackRock Finance, Inc.
2.3%
BVF INC/IL
2.1%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| TAKEDA PHARMACEUTICAL CO LTD |
13F
Company
|
4%
|
$22,972,588
7,531,996 shares
|
— | 31 Mar 2024 |
| EcoR1 Capital, LLC |
13F
Company
|
3.3%
|
$18,658,070
6,117,400 shares
|
— | 31 Mar 2024 |
| Rubric Capital Management LP |
13F
Company
|
2.9%
|
$16,213,705
5,315,969 shares
|
— | 31 Mar 2024 |
| BlackRock Finance, Inc. |
13F
Company
|
2.3%
|
$12,795,631
4,195,289 shares
|
— | 31 Mar 2024 |
| BVF INC/IL |
13F
Company
|
2.1%
|
$11,754,145
3,853,818 shares
|
— | 31 Mar 2024 |
| Madison Avenue Partners, LP |
13F
Company
|
2%
|
$11,127,952
3,648,509 shares
|
— | 31 Mar 2024 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2024
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
72
Shares
46,022,725
Rows available
72
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2024 vs Q1 2024 Across Filers
Q1 2024 holders
80
Q2 2024 holders
72
Holder diff
-8
| Investor | Q1 2024 Shares | Q2 2024 Shares | Share Diff | Share Chg % | Q1 2024 value | Q2 2024 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend